Edition:
United States

AngioDynamics Inc (ANGO.O)

ANGO.O on Nasdaq

17.04USD
9 Dec 2016
Change (% chg)

$-0.07 (-0.41%)
Prev Close
$17.11
Open
$17.07
Day's High
$17.15
Day's Low
$16.86
Volume
319,049
Avg. Vol
288,458
52-wk High
$17.64
52-wk Low
$9.71

Latest Key Developments (Source: Significant Developments)

AngioDynamics reports fiscal 2017 first quarter results
Wednesday, 5 Oct 2016 06:00am EDT 

AngioDynamics Inc : AngioDynamics reports fiscal 2017 first quarter results . Q1 adjusted non-GAAP earnings per share $0.17 . Q1 sales $88.1 million versus I/B/E/S view $86 million . Q1 earnings per share $0.04 . Q1 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $0.62 to $0.65 . FY2017 guidance remains unchanged . FY2017 earnings per share view $0.63, revenue view $358.6 million -- Thomson Reuters I/B/E/S .Sees FY 2017 sales $355 million to $360 million.  Full Article

AngioDynamics names Michael Greiner as new CFO
Monday, 25 Jul 2016 07:35am EDT 

AngioDynamics Inc : AngioDynamics appoints Michael C. Greiner as new chief financial officer .Greiner most recently served as chief financial officer at extreme reach.  Full Article

Intouch Health appoints Joseph Devivo as new CEO
Tuesday, 19 Jul 2016 08:30am EDT 

Intouch Health: Says Intouch Health announces new CEO . Intouch Health says appointed Joseph M. Devivo as its new chief executive officer .Says Devivo was most recently President, CEO and Director Of AngioDynamics.  Full Article

Angiodynamics reports Q4 loss $1.21/shr
Wednesday, 13 Jul 2016 06:00am EDT 

Angiodynamics Inc : Angiodynamics reports fiscal 2016 fourth quarter and full year results . Sees Q1 adjusted shr $0.11 to $0.14 . Q4 shr loss $1.21 . Sees Q1 sales $84 mln to $87 mln . Q4 sales $93.4 mln vs I/B/E/S view $88.4 mln . Q4 shr view $0.16 -- thomson reuters I/B/E/S . Sees FY 2017 adjusted shr $0.62 to $0.65 . Q4 adjusted non-GAAP shr $0.19 excluding items . Sees FY 2017 sales $355 mln to $360 mln . Sees FY2017 free cash flow guidance of greater than $30 mln . FY2017 shr view $0.66, rev view $358.6 mln -- Thomson Reuters I/B/E/S .Q1 shr view $0.14, rev view $86.4 mln -- Thomson Reuters I/B/E/S.  Full Article

AngioDynamics Inc lowers FY 2016 guidance; gives Q3 2016 guidance below analysts' estimates
Thursday, 7 Jan 2016 04:01pm EST 

AngioDynamics Inc:Revised FY 2016 net sales guidance to $353 to $359 million and adjusted earnings per share (EPS) of $0.59 to $0.63.expects Q3 2016 net sales to be in the range of $84 to $87 million and adjusted EPS of $0.10 to $0.14.Q3 2016 revenue of $92 million and EPS of $0.17 - Thomson Reuters I/B/E/S.FY 2016 revenue of $363 million and EPS of $0.62 - Thomson Reuters I/B/E/S.  Full Article

AngioDynamics Inc says CFO Mark Frost resigned
Monday, 9 Nov 2015 08:30am EST 

AngioDynamics Inc:Announces resignation of CFO and appointment of interim CFO.Says CFO Mark Frost Resigned.Michael trimarchi will serve as interim CFO.  Full Article

AngioDynamics Inc announces the approval of the NanoKnife System in South Korea
Thursday, 15 Oct 2015 07:00am EDT 

AngioDynamics Inc:Announces the Approval of the NanoKnife System in South Korea.Says has already begun selling the Nanoknife System to healthcare providers in South Korea through exclusive distribution partnerships.  Full Article

AngioDynamics Inc reiterates FY 2016 guidance; gives Q2 2016 guidance; revenue guidance below analysts' estimates
Thursday, 8 Oct 2015 04:01pm EDT 

AngioDynamics Inc:Reiterates FY2016 revenue guidance of $364 - $370 million and adjusted earnings per share (EPS) without amortization of $0.62 - $0.66.Anticipating revenue to range from $87 million to $91 million in Q2 2016.Says Guiding Q2 2016 adjusted EPS without amortization to be in the range of $0.13 to $0.15.Q2 2016 revenue of $92 million and EPS of $0.16 - Thomson Reuters I/B/E/S.FY 2016 revenue of $365 million and EPS of $0.64 - Thomson Reuters I/B/E/S.  Full Article

AngioDynamics Inc begins shipment of New Midline Catheters
Tuesday, 4 Aug 2015 06:30am EDT 

AngioDynamics Inc:Says launch of BioFlo Midline catheter indicated for short-term intravenous therapies.Says FDA granted 510(k) clearance for BioFlo Midline catheter earlier this year.BioFlo Midline catheter often delivers the same medications, including a variety of antibiotics, as a peripheral intravenous catheter (PIV.).However, Midlines can provide access for up to thirty days while PIVs typically need to be replaced every couple of days, usually due to performance failure.Midline catheters are ideal for patients who may require more than five days of intravenous therapy.  Full Article

AngioDynamics Inc gives FY 2016 guidance; gives Q1 2016 guidance below analysts' estimates
Thursday, 16 Jul 2015 04:01pm EDT 

AngioDynamics Inc:Expects FY 2016 net sales will range between $364 million to $370 million.Anticipates FY 2016 adjusted earnings per share (EPS) without amortization to be $0.62-$0.66.Expects Q1 2016 net sales to range between $83 million and $87 million.Expects Q1 2016 Adjusted EPS without amortization to be in the range of $0.10 - $0.12.Q1 2016 revenue of $88 million and EPS of $0.14 - Thomson Reuters I/B/E/S.FY 2016 revenue of $368 million and EPS of $0.65 - Thomson Reuters I/B/E/S.  Full Article

BRIEF-AngioDynamics prices 2.5 mln share offering at $16 per share

* Says priced 2.5 million shares of common stock at a price to public of $16.00 per share